Drug Trial Radar · NCT03316222
Study of GNS561 in Patients With Liver Cancer
Last checked: Nov 19, 2026Latest source record: May 2, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
50
Actual
Start
Apr 4, 2018
Primary completion
Jan 15, 2021
Study completion Apr 25, 2022
Sponsor
- Lead sponsor
- Genoscience PharmaIndustry
- Sponsor type
- Industry
- First posted
- Oct 20, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a first in human, open-label dose escalation study to investigate the safety, tolerability and pharmacokinetics of GNS561 in patients Primary and Secondary liver cancer
Conditions
- Hepatocellular Carcinoma
- Cholangiocarcinoma, Intrahepatic
Interventions
GNS561Drug
Escalating doses to be administered 3 times a week.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose-Limiting ToxicityTime frame: Dose-Limiting Toxicity will be evaluated during the 4 - week dose escalation phase.
Locations
5 sites in 3 countries. Site status is shown where the registry gives one.
Memorial Sloan Kettering
New York, New York
Jules Bordet Institute
Brussels, Belgium
CHU Grenoble
Grenoble, France
Croix-Rousse Hospital
Lyon, France
Saint-Joseph Hospital
Paris, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.